- US12527795utility2026Compositions of Adagrasib and Mtor Inhibitors and Methods of Treatment Therewith0 cites
- US12485122utility2025Combination of Palbociclib and Adagrasib for Lung Cancer0 cites
- US12466838utility2025Crystalline Form of a Multi-tyrosine Kinase Inhibitor, Method of Preparation, and Use Thereof0 cites
- US12421253utility2025Tetrahydropyridopyrimidine Pan-kras Inhibitors0 cites
- US12421228utility2025Naphthyridine Derivatives as PRC2 Inhibitors0 cites
- US12398154utility2025Azaquinazoline Pan-kras Inhibitors0 cites
- US12383503utility2025Adagrasib Solid Pharmaceutical Compositions0 cites
- US12377101utility2025Combination Therapies0 cites
- US12371435utility2025Substituted Imidazo[1,2-c]pyrimidines as PRC2 Inhibitors0 cites
- US12336995utility2025Combination Therapies0 cites
- US12304915utility2025SOS1 Inhibitors0 cites
- US12286431utility2025Crystalline Forms of a Kras G12C Inhibitor0 cites
- US12280055utility2025Combination Therapies0 cites
- US12281113utility2025Crystalline Forms of a Kras G12C Inhibitor0 cites
- US12252493utility2025Imidazo[1,2-c]pyrimidine Derivatives as PRC2 Inhibitors for Treating Cancer0 cites
- US12208099utility2025Combination Therapies0 cites
- US12171765utility2024Combination Therapies Using PRMT5 Inhibitors for the Treatment of Cancer0 cites
- US12128048utility2024Combination Therapies Using PRMT5 Inhibitors for the Treatment of Cancer0 cites
- US11999753utility2024Tetrahydropyridopyrimidine Pan-kras Inhibitors0 cites
- US11890285utility2024Combination Therapies0 cites
Page 1 of 2Next →